|
|
 |
|
Viewing report
|
|
|
|
Aurobindo Generics Company Intelligence Report
Espicom Business Intelligence Ltd, Jan 2011, Pages: 20
Aurobindo manufactures generics and active pharmaceutical ingredients. The firm's portfolio is spread over six categories: anti-infectives, antiretrovirals, CNS, cardiovascular, gastro-enterological and others.
For fiscal year 2009/10, which ended on 31st March 2010, Aurobindo reported gross sales worth Rs33,196.0 million (US$700.8 million) and total sales worth Rs33,606.5
million (US$709.4 million). These were increases of 15.1% and 20.0%, respectively, over FY2008/09. Profit after tax rose by 319.1% to Rs5,235.7 million (US$110.5
million).
In September 2010, Aurobindo reported that it had entered into licensing and supply agreements with AstraZeneca to supply several solid dosage and sterile products for
emerging markets.
Executive Summary
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Customers who bought this item also bought
Wockhardt Generics Company Intelligence Report
Lupin Generics Company Intelligence Report
Dr Reddy's Laboratories Generics Company Intelligence Report
Sun Pharmaceuticals Generics Company Intelligence Report
Ranbaxy Generics Company Intelligence Report
Company Analysis - Aurobindo Pharma Limited
Cipla Generics Company Intelligence Report
Zydus Cadila Generics Company Intelligence Report
Egis Generics Company Intelligence Report
Teva Pharmaceutical Industries Generics Company Intelligence Report
|
|
|
|
